Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DexCom, Inc. stock logo
DXCM
DexCom
$82.73
-1.0%
$83.03
$57.52
$117.19
$32.44B1.444.40 million shs1.84 million shs
Hologic, Inc. stock logo
HOLX
Hologic
$64.74
-0.9%
$60.58
$51.90
$84.67
$14.43B0.552.37 million shs1.23 million shs
HealthEquity, Inc. stock logo
HQY
HealthEquity
$99.55
-1.7%
$99.47
$65.01
$116.65
$8.61B0.49861,393 shs627,812 shs
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$74.67
+0.2%
$70.51
$60.56
$82.49
$9.09B0.871.72 million shs699,008 shs
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DexCom, Inc. stock logo
DXCM
DexCom
-1.02%-2.72%-4.68%+38.28%-25.41%
Hologic, Inc. stock logo
HOLX
Hologic
-0.87%-0.58%+2.69%+6.37%-11.90%
HealthEquity, Inc. stock logo
HQY
HealthEquity
-1.71%-5.06%-4.06%+26.33%+19.14%
Henry Schein, Inc. stock logo
HSIC
Henry Schein
+0.25%+2.07%+5.80%+14.04%+15.24%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
DexCom, Inc. stock logo
DXCM
DexCom
4.9005 of 5 stars
3.55.00.04.72.82.51.9
Hologic, Inc. stock logo
HOLX
Hologic
4.8547 of 5 stars
3.24.00.04.33.43.31.9
HealthEquity, Inc. stock logo
HQY
HealthEquity
3.7446 of 5 stars
3.53.00.00.02.72.51.9
Henry Schein, Inc. stock logo
HSIC
Henry Schein
2.9012 of 5 stars
1.31.00.03.42.31.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
DexCom, Inc. stock logo
DXCM
DexCom
2.95
Moderate Buy$98.5019.06% Upside
Hologic, Inc. stock logo
HOLX
Hologic
2.41
Hold$77.4219.59% Upside
HealthEquity, Inc. stock logo
HQY
HealthEquity
3.00
Buy$118.0918.62% Upside
Henry Schein, Inc. stock logo
HSIC
Henry Schein
2.64
Moderate Buy$79.306.21% Upside

Current Analyst Ratings Breakdown

Latest HOLX, DXCM, HQY, and HSIC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/16/2025
DexCom, Inc. stock logo
DXCM
DexCom
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$102.00
6/5/2025
HealthEquity, Inc. stock logo
HQY
HealthEquity
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$112.00 ➝ $125.00
6/5/2025
HealthEquity, Inc. stock logo
HQY
HealthEquity
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$98.00 ➝ $115.00
6/4/2025
HealthEquity, Inc. stock logo
HQY
HealthEquity
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$94.00 ➝ $104.00
6/4/2025
HealthEquity, Inc. stock logo
HQY
HealthEquity
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$112.00 ➝ $117.00
6/4/2025
HealthEquity, Inc. stock logo
HQY
HealthEquity
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$110.00 ➝ $117.00
6/4/2025
HealthEquity, Inc. stock logo
HQY
HealthEquity
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$110.00 ➝ $125.00
5/30/2025
DexCom, Inc. stock logo
DXCM
DexCom
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$104.00
5/27/2025
Hologic, Inc. stock logo
HOLX
Hologic
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
5/22/2025
DexCom, Inc. stock logo
DXCM
DexCom
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$82.00 ➝ $102.00
5/22/2025
HealthEquity, Inc. stock logo
HQY
HealthEquity
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$105.00 ➝ $112.00
(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
DexCom, Inc. stock logo
DXCM
DexCom
$4.15B7.82$2.22 per share37.19$5.38 per share15.38
Hologic, Inc. stock logo
HOLX
Hologic
$4.03B3.58$5.45 per share11.87$22.09 per share2.93
HealthEquity, Inc. stock logo
HQY
HealthEquity
$1.20B7.17$4.19 per share23.76$24.56 per share4.05
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$12.67B0.72$7.35 per share10.16$32.33 per share2.31
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
DexCom, Inc. stock logo
DXCM
DexCom
$576.20M$1.3461.7433.631.7812.90%30.05%10.00%7/24/2025 (Estimated)
Hologic, Inc. stock logo
HOLX
Hologic
$789.50M$2.3727.3114.012.3913.83%19.71%10.87%8/4/2025 (Estimated)
HealthEquity, Inc. stock logo
HQY
HealthEquity
$96.70M$1.3772.6635.051.569.80%11.01%6.77%9/2/2025 (Estimated)
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$390M$3.2023.3314.872.403.21%14.87%5.82%8/5/2025 (Estimated)

Latest HOLX, DXCM, HQY, and HSIC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/24/2025Q2 2025
DexCom, Inc. stock logo
DXCM
DexCom
$0.45N/AN/AN/A$1.13 billionN/A
6/3/2025Q1 2026
HealthEquity, Inc. stock logo
HQY
HealthEquity
$0.81$0.97+$0.16$0.61$322.25 million$330.80 million
5/5/2025Q1 2025
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$1.11$1.15+$0.04$0.88$3.24 billion$3.17 billion
5/1/2025Q1 2025
DexCom, Inc. stock logo
DXCM
DexCom
$0.33$0.32-$0.01$0.27$1.02 billion$1.04 billion
5/1/2025Q2 2025
Hologic, Inc. stock logo
HOLX
Hologic
$1.02$1.03+$0.01-$0.08$1.00 billion$1.01 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
Hologic, Inc. stock logo
HOLX
Hologic
N/AN/AN/AN/AN/A
HealthEquity, Inc. stock logo
HQY
HealthEquity
N/AN/AN/AN/AN/A
Henry Schein, Inc. stock logo
HSIC
Henry Schein
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
DexCom, Inc. stock logo
DXCM
DexCom
0.55
1.50
1.32
Hologic, Inc. stock logo
HOLX
Hologic
0.54
3.24
2.52
HealthEquity, Inc. stock logo
HQY
HealthEquity
0.50
4.06
4.06
Henry Schein, Inc. stock logo
HSIC
Henry Schein
0.50
1.38
0.75

Institutional Ownership

CompanyInstitutional Ownership
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
Hologic, Inc. stock logo
HOLX
Hologic
94.73%
HealthEquity, Inc. stock logo
HQY
HealthEquity
99.55%
Henry Schein, Inc. stock logo
HSIC
Henry Schein
96.62%

Insider Ownership

CompanyInsider Ownership
DexCom, Inc. stock logo
DXCM
DexCom
0.32%
Hologic, Inc. stock logo
HOLX
Hologic
1.88%
HealthEquity, Inc. stock logo
HQY
HealthEquity
1.50%
Henry Schein, Inc. stock logo
HSIC
Henry Schein
1.08%
CompanyEmployeesShares OutstandingFree FloatOptionable
DexCom, Inc. stock logo
DXCM
DexCom
10,300392.11 million390.85 millionOptionable
Hologic, Inc. stock logo
HOLX
Hologic
7,063222.85 million218.66 millionOptionable
HealthEquity, Inc. stock logo
HQY
HealthEquity
3,12086.47 million85.18 millionOptionable
Henry Schein, Inc. stock logo
HSIC
Henry Schein
25,000121.72 million120.41 millionOptionable

Recent News About These Companies

Head-To-Head Comparison: Henry Schein (HSIC) & Its Rivals
Henry Schein, Inc. (HSIC) - Yahoo Finance
Is Henry Schein Stock Outperforming the Dow?

New MarketBeat Followers Over Time

Media Sentiment Over Time

DexCom stock logo

DexCom NASDAQ:DXCM

$82.73 -0.85 (-1.02%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$82.87 +0.14 (+0.17%)
As of 07/3/2025 04:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Hologic stock logo

Hologic NASDAQ:HOLX

$64.74 -0.57 (-0.87%)
As of 07/3/2025 03:46 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, specimen radiology, and connectivity solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, the company offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

HealthEquity stock logo

HealthEquity NASDAQ:HQY

$99.55 -1.73 (-1.71%)
Closing price 07/3/2025 03:44 PM Eastern
Extended Trading
$100.64 +1.10 (+1.10%)
As of 07/3/2025 04:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HealthEquity, Inc. provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts. It also provides investment platform; and online-only automated investment advisory services through Advisor, a Web-based tool. In addition, the company offers flexible spending accounts; health reimbursement arrangements; and Consolidated Omnibus Budget Reconciliation Act continuation services, as well as administers pre-tax commuter benefit programs. It serves clients through a direct sales force; benefits brokers and advisors; and a network of health plans, benefits administrators, benefits brokers and consultants, and retirement plan record-keepers. HealthEquity, Inc. was incorporated in 2002 and is based in Draper, Utah.

Henry Schein stock logo

Henry Schein NASDAQ:HSIC

$74.67 +0.19 (+0.25%)
Closing price 07/3/2025 03:25 PM Eastern
Extended Trading
$74.61 -0.05 (-0.07%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Henry Schein, Inc. provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products, such as branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners; and value-added practice solutions comprising practice consultancy, education, revenue cycle management and financial services, e-services, practice technology, and network and hardware services, as well as consulting, and continuing education services. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.